A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Abb Vie Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 234,206 shares of ABBV stock, worth $40.2 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
234,206
Previous 233,430 0.33%
Holding current value
$40.2 Million
Previous $40 Million 15.52%
% of portfolio
0.24%
Previous 0.23%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$163.84 - $199.33 $127,139 - $154,680
776 Added 0.33%
234,206 $46.3 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $5.55 Million - $6.48 Million
35,831 Added 18.13%
233,430 $40 Million
Q1 2024

May 15, 2024

BUY
$159.82 - $182.1 $31.6 Million - $36 Million
197,599 New
197,599 $35.4 Billion
Q4 2023

Aug 14, 2024

BUY
$137.6 - $154.97 $155,212 - $174,806
1,128 Added 0.6%
187,969 $29.1 Billion
Q3 2023

Aug 14, 2024

BUY
$133.59 - $154.65 $1.11 Million - $1.28 Million
8,309 Added 4.65%
186,841 $27.9 Billion
Q2 2023

Aug 14, 2024

SELL
$132.51 - $164.9 $1.37 Million - $1.71 Million
-10,358 Reduced 5.48%
178,532 $24.1 Billion
Q1 2023

Aug 14, 2024

BUY
$144.61 - $166.54 $4.07 Million - $4.69 Million
28,174 Added 17.53%
188,890 $30.1 Billion
Q4 2022

Aug 14, 2024

SELL
$138.31 - $165.87 $5.4 Million - $6.47 Million
-39,032 Reduced 19.54%
160,716 $26 Billion
Q3 2022

Aug 14, 2024

BUY
$134.21 - $153.93 $281,035 - $322,329
2,094 Added 1.06%
199,748 $26.8 Billion
Q2 2022

Aug 14, 2024

SELL
$137.62 - $174.96 $545,112 - $693,016
-3,961 Reduced 1.96%
197,654 $30.3 Billion
Q1 2022

Aug 14, 2024

SELL
$131.98 - $163.75 $4.2 Million - $5.21 Million
-31,815 Reduced 13.63%
201,615 $32.7 Billion
Q4 2021

Aug 30, 2024

BUY
$107.43 - $135.93 $482,468 - $610,461
4,491 Added 1.84%
248,491 $33.6 Billion
Q3 2021

Aug 30, 2024

BUY
$106.4 - $120.78 $1.51 Million - $1.71 Million
14,155 Added 6.16%
244,000 $26.3 Billion
Q2 2021

Aug 30, 2024

SELL
$105.21 - $117.21 $377,177 - $420,197
-3,585 Reduced 1.54%
229,845 $25.9 Billion
Q1 2021

Aug 30, 2024

BUY
$102.3 - $112.62 $1.82 Million - $2 Million
17,751 Added 8.45%
227,772 $24.7 Billion
Q4 2020

Aug 30, 2024

BUY
$80.49 - $108.67 $2.95 Million - $3.99 Million
36,697 Added 21.17%
210,021 $22.5 Billion
Q3 2020

Aug 30, 2024

BUY
$85.91 - $100.83 $612,881 - $719,321
7,134 Added 4.29%
173,324 $15.2 Billion
Q2 2020

Aug 30, 2024

BUY
$73.37 - $98.18 $1.39 Million - $1.86 Million
18,966 Added 12.88%
166,190 $16.3 Billion
Q1 2020

Aug 30, 2024

SELL
$64.5 - $97.79 $298,764 - $452,963
-4,632 Reduced 3.05%
147,224 $11.2 Billion
Q4 2019

Aug 30, 2024

SELL
$72.13 - $90.25 $50,274 - $62,904
-697 Reduced 0.46%
151,856 $13.4 Billion
Q3 2019

Aug 30, 2024

BUY
$62.98 - $75.72 $836,815 - $1.01 Million
13,287 Added 9.54%
152,553 $11.6 Billion
Q2 2019

Aug 30, 2024

BUY
$65.7 - $83.98 $216,087 - $276,210
3,289 Added 2.42%
139,266 $10.1 Billion
Q1 2019

Aug 30, 2024

BUY
$77.14 - $90.79 $1.09 Million - $1.29 Million
14,190 Added 11.65%
135,977 $11 Billion
Q4 2018

Aug 30, 2024

SELL
$77.85 - $96.01 $8.69 Million - $10.7 Million
-111,643 Reduced 47.83%
121,787 $11.2 Billion
Q3 2018

Aug 30, 2024

SELL
$88.91 - $98.84 $214,895 - $238,896
-2,417 Reduced 3.76%
61,888 $5.85 Billion
Q2 2018

Aug 30, 2024

SELL
$89.78 - $106.23 $266,197 - $314,971
-2,965 Reduced 4.41%
64,305 $5.96 Billion
Q1 2018

Aug 30, 2024

SELL
$92.01 - $123.21 $686,026 - $918,653
-7,456 Reduced 9.98%
67,270 $6.37 Billion
Q4 2017

Aug 30, 2024

BUY
$89.56 - $98.21 $460,965 - $505,486
5,147 Added 7.4%
74,726 $7.23 Billion
Q3 2017

Aug 30, 2024

BUY
$69.85 - $89.22 $207,873 - $265,518
2,976 Added 4.47%
69,579 $6.18 Billion
Q2 2017

Aug 30, 2024

SELL
N/A
-5,957 Reduced 8.21%
66,603 $4.83 Billion
Q1 2017

Aug 30, 2024

SELL
N/A
-160,870
72,560 $4.73 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $303B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.